Literature DB >> 2155314

SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results.

K J Langen1, H H Coenen, N Roosen, P Kling, O Muzik, H Herzog, T Kuwert, G Stöcklin, L E Feinendegen.   

Abstract

L-3-[123I]iodo-alpha-methyltyrosine (123IMT) like tyrosine has been reported previously to have a high affinity for a transport system in the blood-brain-barrier (BBB). We examined the kinetic behavior of 124IMT in brain and plasma in two patients with glioblastoma using dynamic positron emission tomography (PET). 124IMT accumulated in brain and tumor tissue, reaching a maximum after 15 min, with a washout of 20% to 35% at 60 min postinjection. Animal experiments confirmed the accumulation of the intact tracer in murine brain, but there was no incorporation into proteins. SPECT studies with 123IMT in patients with different types of brain tumors showed increased uptake in 26 of 32 tumors. Although nonspecific uptake in tumors must be considered, the accumulation of IMT in normal brain and in some tumors with intact BBB suggests a specific uptake of IMT. As transport is the main determinant of initial amino acid uptake, 123IMT appears to be a suitable SPECT tracer of amino acid uptake although it is not incorporated into protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155314

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

2.  Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging.

Authors:  H Herzog; S M Qaim; L Tellmann; S Spellerberg; D Kruecker; H H Coenen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-15       Impact factor: 9.236

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

4.  Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system.

Authors:  Rebecca A Gregory; Claire A Hooker; Mike Partridge; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-14       Impact factor: 9.236

Review 5.  The production of [124I]iodine and [86Y]yttrium.

Authors:  Jochen Schmitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

6.  Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors.

Authors:  Weiping Yu; Jonathan McConathy; Larry Williams; Vernon M Camp; Eugene J Malveaux; Zhaobin Zhang; Jeffrey J Olson; Mark M Goodman
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

7.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

Review 8.  Prediction of brain tumor therapy response by PET.

Authors:  R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  The role of nuclear medicine in oncology.

Authors:  H J Biersack; B Briele; A L Hotze; P Oehr; L Qian; M A Mekkawy; W J Shih
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

10.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.